Although transformed SCLC (t-SCLC) shares several histopathological features with de novo SCLC—including a high nuclear-to-cytoplasmic ratio, expression of neuroendocrine markers, and frequent inactivation of tumor suppressor genes RB1 and TP53—it is increasingly recognized as a distinct clinical entity. Here, TP53 is linked to small cell lung carcinoma.